Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Active-controlled, Parallel Group, 16-Week Open Label Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo (Insulin Glargine-U300) Versus Lantus in Patients With Type 1 Diabetes Mellitus

NCT02688933 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT02688933
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02688933 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Active-controlled, Parallel Group, 16-Week Open Label Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo (Insulin Glargine-U300) Versus Lantus in Patients With Type 1 Diabetes Mellitus
Lead sponsor
Sanofi
Phase
Phase 4
Overall status
Completed
Start date
May 5, 2016
Completion date
June 19, 2017
Enrollment
638 (actual)
Sites
100

Conditions

As the registry lists them; a condition with its own page is linked.

type 1 diabetes mellitus